Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid

Abstract Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer´s disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET sign...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research. Neuroimaging 2017-07, Vol.265, p.98-101
Main Authors: Schipke, Carola G, Koglin, Norman, Bullich, Santiago, Joachim, Lisa Katharina, Haas, Brigitte, Seibyl, John, Barthel, Henryk, Sabri, Osama, Peters, Oliver
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - diagnosis
Alzheimer's disease
Amyloid beta-Peptides - cerebrospinal fluid
Aniline Compounds
Beta-amyloid
Biomarker
Biomarkers - cerebrospinal fluid
Brain - diagnostic imaging
Brain - pathology
Cerebrospinal fluid
Florbetaben
Humans
Middle Aged
Peptide Fragments - cerebrospinal fluid
PET-tracer
Positron-Emission Tomography - methods
Psychiatry
Radiology
Reproducibility of Results
Sensitivity and Specificity
Stilbenes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer´s disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the18 F-labelled tracer florbetaben (NeuraCeqTM ), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 34 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.
ISSN:0925-4927
1872-7506
DOI:10.1016/j.pscychresns.2016.10.011